Welcome to your Drug Excretion, Pharmacodynamics & Receptor Principles Arena
1.
A patient receives a full agonist together with another drug that binds to the same receptor and activates it weakly. As the concentration of the second drug increases, the overall response falls despite continued receptor occupancy. Which property of the second drug best explains this effect?
2.
An experimental receptor shows spontaneous activity even when no endogenous ligand is present. Drug A reduces this basal activity, whereas Drug B binds to the receptor without altering basal activity but prevents an agonist from acting. Which statement best distinguishes Drug A from Drug B?
3.
A patient is receiving a drug whose elimination pathway becomes saturated at high plasma concentrations. A small increase in dose produces a disproportionately large rise in plasma concentration. Which pharmacokinetic principle best explains this?
4.
A patient exposed to a toxic metal is treated with an agent that directly binds the metal and forms a less biologically active complex. The protective effect does not depend on receptor blockade. Which type of antagonism is demonstrated?
5.
A 55-year-old patient begins regular therapy with a drug that follows first-order kinetics and has a half-life of 12 hours. No loading dose is given. When will the plasma concentration be expected to be close to steady state?
6.
A drug has an ED50 of 5 mg and a TD50 of 40 mg. A second drug used for the same indication has an ED50 of 10 mg and a TD50 of 30 mg. Based only on therapeutic index, which conclusion is most appropriate?
7.
A drug produces therapeutic benefit in 99% of a population at 20 mg, while toxicity begins to appear in 1% of the population at 60 mg. Which measure most directly uses these two values to assess drug safety?
8.
A clinical trial records whether each participant achieves adequate pain relief after receiving increasing doses of an analgesic. At one dose, exactly half of the participants achieve the predefined therapeutic endpoint. Which value does this dose represent?
9.
A pharmacologist constructs a graded dose-response curve for an agonist in isolated smooth muscle. The experiment provides useful information about potency and maximal response but cannot determine how many patients in a population will achieve a predefined therapeutic effect. Which method would address this limitation?
10.
A 68-year-old man with reduced renal function is receiving a drug mainly eliminated unchanged in urine. The same maintenance dose is continued despite a marked fall in renal clearance. Which pharmacokinetic consequence is most likely?
11.
A patient receives a β2-adrenoceptor agonist that activates a membrane receptor coupled to a stimulatory G protein. Which sequence most directly links receptor activation to the intracellular response?
12.
A patient receiving lithium develops toxicity after a relatively small increase in drug exposure. The prescribing team emphasizes that effective and toxic concentrations lie close together. Which pharmacodynamic concept best explains the need for careful monitoring?
13.
Histamine causes bronchial smooth-muscle contraction through histamine receptors. A β2-adrenoceptor agonist is given and produces bronchodilation through a different receptor system. Which type of antagonistic interaction best describes these opposing effects?
14.
Two agonists act at the same receptor. Drug A produces a maximal response of 100 units, whereas Drug B reaches only 60 units despite increasing its concentration until no further effect occurs. What best explains the lower maximal response of Drug B?
15.
A patient with epilepsy receives phenytoin. After a small dose increase, the plasma concentration rises much more than expected. Which property of phenytoin best explains this finding?
16.
A child weighs 45 lb and requires a drug whose usual adult dose is 600 mg. Which dose is obtained using Clark's formula?
17.
A drug follows first-order kinetics. Its plasma concentration is 80 mg/L at the start of observation and its half-life is 4 hours. What concentration is expected after 12 hours?
18.
A drug is being eliminated at 24 mg/hour while its plasma concentration is 6 mg/L. Which value represents its total clearance?
19.
A highly plasma protein-bound drug is present in the circulation. Which portion is most directly available for glomerular filtration?
20.
A patient receiving long-term drug therapy has reached steady state. The maintenance dosing rate is doubled while clearance remains unchanged. After sufficient time, what is the expected pharmacokinetic effect?
21.
A patient is taking a drug that blocks β-adrenoceptors for several months. The drug is suddenly discontinued, and the patient develops exaggerated sympathetic effects. Which receptor change most likely contributed to this response?
22.
A drug is filtered freely at the glomerulus but is subsequently reabsorbed from the renal tubule because much of it remains lipid soluble and non-ionized. What will be the effect of this reabsorption on renal excretion?
23.
A patient receives a drug that initially produces a strong receptor-mediated response. After prolonged continuous exposure, the same concentration produces a progressively smaller effect because fewer functional receptors remain on the cell surface. Which adaptation best explains this finding?
24.
A drug activates a receptor coupled to phospholipase C. Shortly afterward, intracellular calcium concentration rises and protein kinase C is activated. Which pair of signaling molecules is most directly responsible?
25.
A drug selectively stimulates one adrenergic receptor subtype at low therapeutic concentrations. At higher concentrations, additional adrenergic receptor subtypes are activated and unwanted effects appear. Which pharmacological principle best explains this change?
26.
A patient is receiving a drug with a volume of distribution of 60 L and clearance of 6 L/hour. Which is the approximate plasma half-life?
27.
An agonist is tested before and after addition of an antagonist. After the antagonist is added, increasing the agonist concentration fails to restore the original maximum response. Which change in the dose-response curve most strongly supports non-competitive antagonism?
28.
A drug has a long plasma half-life. A clinician changes the maintenance dose and reviews the plasma concentration several hours later. The concentration has changed only slightly. Which explanation is most appropriate?
29.
A 7-year-old child requires a medicine whose usual adult dose is 400 mg. Using Young's formula, which is the closest calculated dose?
30.
A drug has a volume of distribution of 80 L and a clearance of 8 L/hour. A second drug has the same clearance but a volume of distribution of 40 L. Which statement is most likely correct?
31.
A researcher compares two bronchodilators using log dose-response curves. Drug X reaches the same maximum bronchodilator response as Drug Y, but its curve lies to the left of Drug Y. Which interpretation is most appropriate?
32.
An agonist produces a maximal response in cardiac tissue when only a fraction of available receptors are occupied. A small reduction in receptor number initially has little effect on the maximum response. Which concept best explains this observation?
33.
A pharmacologist studies an agonist in isolated tissue. Addition of a second drug shifts the agonist log dose-response curve to the right without reducing the maximum response. Increasing the agonist concentration restores the original maximal effect. Which interaction is most likely?
34.
Two drugs have the same volume of distribution. Drug X has twice the clearance of Drug Y. Which relationship between their half-lives is most likely?
35.
A patient receives repeated doses of a drug. The target plasma concentration is 4 mg/L, clearance is 5 L/hour, dosing interval is 6 hours, and oral bioavailability is 0.5. What maintenance dose is required?
36.
An 8-year-old child is prescribed a drug for which the adult dose is 500 mg. Which dose is obtained using Dilling's formula?
37.
A patient receives a drug that is actively secreted into the proximal tubule by a carrier system. Another drug using the same transporter is introduced. Which consequence is most likely?
38.
A patient receiving a drug at a constant dosing rate reaches a stable average plasma concentration. Renal function subsequently deteriorates, reducing total drug clearance, while the dose and dosing interval remain unchanged. Which change is expected?
39.
A new drug is compared with an established drug for the same therapeutic purpose. The new drug requires a lower dose to produce an effect but cannot produce as great a maximum response as the established drug. Which statement best describes the new drug?
40.
A student compares two drugs. Drug A follows first-order kinetics, while Drug B undergoes capacity-limited zero-order elimination. Which statement best differentiates their elimination patterns?
